{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:25:32Z","timestamp":1793316332450,"version":"4.5.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-23864-5","type":"journal-article","created":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T21:06:41Z","timestamp":1763413601000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Cost-effectiveness of finotonlimab plus chemotherapy versus chemotherapy alone for recurrent or metastatic head and neck cancer in China"],"prefix":"10.1038","volume":"15","author":[{"given":"Yu","family":"Zeng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aixin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keqin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,17]]},"reference":[{"issue":"1","key":"23864_CR1","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41572-020-00224-3","volume":"6","author":"DE Johnson","year":"2020","unstructured":"Johnson, D. E. et al. Head and neck squamous cell carcinoma. Nat. Rev. Dis. Primers. 6(1), 92 (2020).","journal-title":"Nat. Rev. Dis. Primers."},{"issue":"3","key":"23864_CR2","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s40265-023-01835-2","volume":"83","author":"A Bhatia","year":"2023","unstructured":"Bhatia, A. & Burtness, B. Treating Head and Neck Cancer in the Age of Immunotherapy: A 2023 Update. Drugs 83(3), 217\u2013248 (2023).","journal-title":"Drugs"},{"key":"23864_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2020.102984","volume":"153","author":"A Lau","year":"2020","unstructured":"Lau, A., Yang, W. F., Li, K. Y. & Su, Y. X. Systemic Therapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma- A Systematic Review and Meta-Analysis. Crit. Rev. Oncol. Hematol. 153, 102984 (2020).","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"10167","key":"23864_CR4","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/S0140-6736(18)31999-8","volume":"393","author":"EEW Cohen","year":"2019","unstructured":"Cohen, E. E. W. et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): A randomised, open-label, phase 3 study. Lancet 393(10167), 156\u2013167 (2019).","journal-title":"Lancet"},{"key":"23864_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115395","volume":"221","author":"M Tahara","year":"2025","unstructured":"Tahara, M. et al. Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: 5-year follow-up from the randomized phase III KEYNOTE-048 study. Eur. J. Cancer. 221, 115395 (2025).","journal-title":"Eur. J. Cancer."},{"issue":"4","key":"23864_CR6","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.21037\/tlcr-24-1042","volume":"14","author":"B Han","year":"2025","unstructured":"Han, B. et al. Efficacy and safety of finotonlimab plus docetaxel vs docetaxel in previously treated advanced squamous cell non-small-cell lung cancer: a randomized, double-blinded, phase III trial. Transl. Lung Cancer Res. 14(4), 1231\u20131241 (2025).","journal-title":"Transl. Lung Cancer Res."},{"issue":"9","key":"23864_CR7","doi-asserted-by":"publisher","first-page":"2568","DOI":"10.1038\/s41591-024-03110-7","volume":"30","author":"Y Shi","year":"2024","unstructured":"Shi, Y. et al. Finotonlimab with chemotherapy in recurrent or metastatic head and neck cancer: A randomized phase 3 trial. Nat. Med. 30(9), 2568\u20132575 (2024).","journal-title":"Nat. Med."},{"key":"23864_CR8","doi-asserted-by":"crossref","unstructured":"Yao Y, Yang X, Li J, Guo E, Wang H, Sun C, et al. Preclinical Characterization of Efficacy and Pharmacodynamic Properties of Finotonlimab, a Humanized Anti-PD-1 Monoclonal Antibody. Pharmaceuticals (Basel). 2025;18(3).","DOI":"10.3390\/ph18030395"},{"key":"23864_CR9","doi-asserted-by":"publisher","first-page":"1333128","DOI":"10.3389\/fphar.2024.1333128","volume":"15","author":"W Tian","year":"2024","unstructured":"Tian, W. et al. Cost-effectiveness of tumor-treating fields plus standard therapy for advanced non-small cell lung cancer progressed after platinum-based therapy in the United States. Front. Pharmacol. 15, 1333128 (2024).","journal-title":"Front. Pharmacol."},{"key":"23864_CR10","doi-asserted-by":"publisher","first-page":"1268070","DOI":"10.3389\/fimmu.2023.1268070","volume":"14","author":"W Tian","year":"2023","unstructured":"Tian, W. et al. Cost-effectiveness of neoadjuvant pembrolizumab plus chemotherapy with adjuvant pembrolizumab for early-stage non-small cell lung cancer in the United States. Front. Immunol. 14, 1268070 (2023).","journal-title":"Front. Immunol."},{"issue":"12","key":"23864_CR11","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-038867","volume":"10","author":"W Xin","year":"2020","unstructured":"Xin, W. et al. Cost-effectiveness of pembrolizumab for treatment of platinum-resistant recurrent or metastatic head and neck squamous cell carcinoma in China: an economic analysis based on a randomised, open-label, phase III trial. BMJ Open 10(12), e038867 (2020).","journal-title":"BMJ Open"},{"issue":"2","key":"23864_CR12","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1017\/S0266462300105094","volume":"17","author":"DH Smith","year":"2001","unstructured":"Smith, D. H. & Gravelle, H. The practice of discounting in economic evaluations of healthcare interventions. Int. J. Technol. Assess Health Care. 17(2), 236\u2013243 (2001).","journal-title":"Int. J. Technol. Assess Health Care."},{"key":"23864_CR13","doi-asserted-by":"publisher","first-page":"1590319","DOI":"10.3389\/fonc.2025.1590319","volume":"15","author":"L Huo","year":"2025","unstructured":"Huo, L. et al. Adoptive cellular immunotherapy combined with chemotherapy versus chemotherapy alone in Chinese patients with metastatic colorectal cancer: a cost-effectiveness analysis to inform drug pricing. Front Oncol. 15, 1590319 (2025).","journal-title":"Front Oncol."},{"issue":"3","key":"23864_CR14","doi-asserted-by":"publisher","first-page":"e456","DOI":"10.1016\/S2214-109X(22)00554-X","volume":"11","author":"H Liu","year":"2023","unstructured":"Liu, H. et al. Economic evaluation of combined population-based screening for multiple blindness-causing eye diseases in China: A cost-effectiveness analysis. Lancet. Glob. Health 11(3), e456\u2013e465 (2023).","journal-title":"Lancet. Glob. Health"},{"key":"23864_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2022.105842","volume":"128","author":"K Tian","year":"2022","unstructured":"Tian, K., Han, J., Wang, Z. & Chen, J. Immune checkpoint inhibition in first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: A CAPTAIN-1st and JUPITER-02 trial-based cost-effectiveness analysis. Oral Oncol. 128, 105842 (2022).","journal-title":"Oral Oncol."},{"issue":"9","key":"23864_CR16","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1002\/hed.27452","volume":"45","author":"J Han","year":"2023","unstructured":"Han, J. et al. First-line immunotherapy combinations for recurrent or metastatic nasopharyngeal carcinoma: An updated network meta-analysis and cost-effectiveness analysis. Head Neck. 45(9), 2246\u20132258 (2023).","journal-title":"Head Neck."},{"key":"23864_CR17","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.oraloncology.2018.10.032","volume":"87","author":"A Hirschmann","year":"2018","unstructured":"Hirschmann, A. et al. Cost-effectiveness of nivolumab in the treatment of head and neck cancer. Oral Oncol. 87, 104\u2013110 (2018).","journal-title":"Oral Oncol."},{"issue":"5","key":"23864_CR18","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1080\/13696998.2020.1715414","volume":"23","author":"R Haddad","year":"2020","unstructured":"Haddad, R. et al. Cost-effectiveness analysis of nivolumab for the treatment of squamous cell carcinoma of the head and neck in the United States. J. Med Econ. 23(5), 442\u2013447 (2020).","journal-title":"J. Med Econ."},{"issue":"1","key":"23864_CR19","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1186\/s12913-023-09727-7","volume":"23","author":"T Wang","year":"2023","unstructured":"Wang, T., Li, Y. & Zheng, X. Cost-effectiveness of the combination of immunotherapy and chemotherapy for extensive-stage small-cell lung cancer: a systematic review. BMC Health Serv. Res. 23(1), 691 (2023).","journal-title":"BMC Health Serv. Res."},{"key":"23864_CR20","doi-asserted-by":"publisher","first-page":"923619","DOI":"10.3389\/fpubh.2022.923619","volume":"10","author":"YT Lin","year":"2022","unstructured":"Lin, Y. T., Liu, T. X., Chen, J., Wang, C. & Chen, Y. Cost-effectiveness of nivolumab immunotherapy vs paclitaxel or docetaxel chemotherapy as second-line therapy in advanced esophageal squamous cell carcinoma in China. Front Public Health 10, 923619 (2022).","journal-title":"Front Public Health"},{"key":"23864_CR21","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.oraloncology.2019.08.010","volume":"97","author":"J Giuliani","year":"2019","unstructured":"Giuliani, J. & Bonetti, A. Immune-checkpoint inhibitors in head and neck squamous cell carcinoma: Cost-efficacy in second-line treatment based on programmed death-ligand 1 (PD-L1) level. Oral Oncol. 97, 143\u2013145 (2019).","journal-title":"Oral Oncol."},{"key":"23864_CR22","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.oraloncology.2017.09.017","volume":"74","author":"MC Ward","year":"2017","unstructured":"Ward, M. C. et al. Cost-effectiveness of nivolumab for recurrent or metastatic head and neck cancer\u2606. Oral Oncol. 74, 49\u201355 (2017).","journal-title":"Oral Oncol."},{"issue":"1","key":"23864_CR23","doi-asserted-by":"publisher","first-page":"6807","DOI":"10.1038\/s41598-024-57277-7","volume":"14","author":"D Ye","year":"2024","unstructured":"Ye, D., Liang, X., Chen, X. & Li, Y. Nivolumab plus ipilimumab versus the EXTREME regimen in recurrent\/metastatic squamous cell carcinoma of the head and neck: A cost-effectiveness analysis. Sci Rep. 14(1), 6807 (2024).","journal-title":"Sci Rep."},{"key":"23864_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2020.104754","volume":"107","author":"K Zhou","year":"2020","unstructured":"Zhou, K. et al. Pembrolizumab alone or with chemotherapy for squamous cell carcinoma of the head and neck: A cost-effectiveness analysis from Chinese perspective. Oral Oncol. 107, 104754 (2020).","journal-title":"Oral Oncol."},{"issue":"1","key":"23864_CR25","doi-asserted-by":"publisher","first-page":"2482019","DOI":"10.1080\/07853890.2025.2482019","volume":"57","author":"K Xu","year":"2025","unstructured":"Xu, K. et al. Cost-effectiveness of PD-1 inhibitors combined with chemotherapy for first-line treatment of oesophageal squamous cell carcinoma in China: a comprehensive analysis. Ann Med. 57(1), 2482019 (2025).","journal-title":"Ann Med."},{"issue":"1","key":"23864_CR26","doi-asserted-by":"publisher","first-page":"6429","DOI":"10.1038\/s41598-025-90960-x","volume":"15","author":"R Long","year":"2025","unstructured":"Long, R., Guo, H. & Chen, K. Cost-effectiveness analysis of nimotuzumab combined with gemcitabine for K-Ras wild type locally advanced or metastatic pancreatic cancer in China. Sci. Rep. 15(1), 6429 (2025).","journal-title":"Sci. Rep."},{"issue":"4","key":"23864_CR27","doi-asserted-by":"publisher","first-page":"e340","DOI":"10.3747\/co.23.2244","volume":"23","author":"J Amdahl","year":"2016","unstructured":"Amdahl, J., Diaz, J., Park, J., Nakhaipour, H. R. & Delea, T. E. Cost-effectiveness of pazopanib compared with sunitinib in metastatic renal cell carcinoma in Canada. Curr Oncol. 23(4), e340\u2013e354 (2016).","journal-title":"Curr Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-23864-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-23864-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-23864-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T21:06:42Z","timestamp":1763413602000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-23864-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,17]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["23864"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-23864-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,17]]},"assertion":[{"value":"17 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"This research constitutes a cost-effectiveness analysis utilizing a simulation model, ethical approval was not required. The model\u2019s input parameters were entirely obtained from publicly accessible data in existing literature. No primary data collection from human subjects or personal identifiers was performed.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}}],"article-number":"40105"}}